FDA Drug recall D-0251-2015
Lidocaine 18.18 mg/mL/Bupivacaine 2.27 mg/mL/Epinephrine 0.0022 mg/mL/Hyaluronidase13.64 u/mL, supplied in 11 mL Sterile Syringes, Rx only,…
- FDA Drug
- Class I
- terminated
- Published 2014-11-26
On 2014-11-26 the FDA classified a Class I recall of Lidocaine 18.18 mg/mL/Bupivacaine 2.27 mg/mL/Epinephrine 0.0022 mg/mL/Hyaluronidase13.64 u/mL, supplied in 11 mL Sterile Syringes, Rx only,… by Abrams Royal Pharmacy, citing non-Sterility.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0251-2015 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2013-04-19 |
| Published | 2014-11-26 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Abrams Royal Pharmacy |
| Distribution | TX |
Product
Lidocaine 18.18 mg/mL/Bupivacaine 2.27 mg/mL/Epinephrine 0.0022 mg/mL/Hyaluronidase13.64 u/mL, supplied in 11 mL Sterile Syringes, Rx only, Compounded med, Single use only, (Red Block) ABRAMS ROYAL Compounding Pharmacy, Dallas, TX
Reason
Non-Sterility
Identifiers
| code_info | Lot# 041013-13 (also been written as "041013@13") Exp: 06/09/2013 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0251-2015%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.